Internal Reference Number: FOI_8442
Date Request Received: 07/02/2025 00:00:00
Date Request Replied To: 26/02/2025 00:00:00
This response was sent via: By Email
Request Summary: Oncology Breast Cancer
Request Category: Researcher
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Aromatase Inhibitor as a single agent • Atezolizumab • Capecitabine as a single agent • Carboplatin + Paclitaxel • Elacestrant • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab • Pertuzumab (Perteja) + Trastuzumab (Herceptin) • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Trastuzumab deruxtecan (Enhertu) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab emtansine (Kadcyla) • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 22 • Abemaciclib + Fulvestrant 5 • Alpelisib + Fulvestrant <5 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide 6 • Aromatase Inhibitor as a single agent - unable to answer • Atezolizumab 0 • Capecitabine as a single agent 12 • Carboplatin + Paclitaxel <5 • Elacestrant 0 • Eribulin as a single agent or in combination 0 • Everolimus + Exemestane 0 • Fulvestrant as a single agent unable to answer • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 25 • Palbociclib + Fulvestrant <5 • Parp Inhibitors (Olaparib/Talazoparib) 0 • Pembrolizumab 5 • Pertuzumab (Perteja) + Trastuzumab (Herceptin) <5 • Phesgo (Pertuzumab + Trastuzumab in a single injection) 20 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 14 • Ribociclib + Fulvestrant <5 • Sacituzumab Govitecan 5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 6 • Trastuzumab deruxtecan (Enhertu) 5 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel 13 • Trastuzumab emtansine (Kadcyla) <5 • Any other active systemic anti-cancer therapy 25 | |
| Question Number 2: How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies: • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Pertuzumab (Perteja) + Trastuzumab (Herceptin) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab deruxtecan (Enhertu) • Trastuzumab emtansine (Kadcyla) | |
| Answer To Question 2: • Phesgo (Pertuzumab + Trastuzumab in a single injection) 16 • Pertuzumab (Perteja) + Trastuzumab (Herceptin) <5 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel 6 • Trastuzumab deruxtecan (Enhertu) 5 • Trastuzumab emtansine (Kadcyla) 0 | |
| Question Number 3: If breast cancer is not treated at or within the Trust, where are patients referred ? | |
| Answer To Question 3: N/A | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
